The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis

Published:2018-07-10 Issue:3 Volume:58 Page:283-297
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Hermann Robert,Karlsson Mats O.,Novakovic Ana M.,Terranova Nadia,Fluck Markus,Munafo Alain

Funder

EMD Serono

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/article/10.1007/s40262-018-0695-9/fulltext.html

Reference42 articles.

1. Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(Suppl 1):S5–48.

2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.

3. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–26.

4. Giovannoni G, Soelberg-Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of Cladribine Tablets in patients with relapsing–remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. https://doi.org/10.1177/1352458517727603 (Epub 1 Aug 2017).

5. Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13(3):257–67.

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Performing a physiologically relevant test for cladribine tablets;Drug development & registration;2024-08-15

2. Pharmacological modulation of inflammatory oligodendrocyte progenitor cells using three multiple sclerosis disease modifying therapies in vitro;Neurotherapeutics;2024-07

3. CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis;Frontiers in Immunology;2024-02-09

4. The Development of the Combination Drug Leukovir® Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review;Current Drug Targets;2023-12

5. Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis;Journal of Controlled Release;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3